Yes, Entresto Treats Heart Failure
Entresto (sacubitril/valsartan) is FDA-approved to reduce the risk of cardiovascular death and hospitalization in adults with chronic heart failure with reduced ejection fraction (HFrEF), typically NYHA class II-IV.[1] It's also approved for children aged 1 year and older with symptomatic chronic HFrEF.[2]
How Entresto Works in Heart Failure
Entresto combines a neprilysin inhibitor (sacubitril) and an angiotensin receptor blocker (valsartan). Sacubitril boosts natriuretic peptides to promote vasodilation and natriuresis, while valsartan blocks angiotensin II effects. This dual action reduces cardiac strain more effectively than ACE inhibitors or ARBs alone in HFrEF patients.[3]
Who Qualifies for Entresto
Primarily for HFrEF patients (ejection fraction ≤40%) on standard therapy, including beta-blockers and diuretics. It's not approved for heart failure with preserved ejection fraction (HFpEF) or acute decompensated heart failure.[1][4] Guidelines from ACC/AHA recommend it as first-line therapy for eligible HFrEF patients.[5]
Key Clinical Evidence
The PARADIGM-HF trial showed Entresto reduced cardiovascular death or HF hospitalization by 20% versus enalapril in 8,442 HFrEF patients.[6] PARAGON-HF found modest benefits in HFpEF but didn't lead to approval there.[7] Long-term data confirm sustained risk reduction.[3]
Common Side Effects and Risks
Patients report hypotension (14%), hyperkalemia (10-12%), cough (less than ACE inhibitors), and angioedema (rare). Monitor kidney function and potassium; avoid in pregnancy due to fetal toxicity.[1][4] Stopping abruptly can worsen heart failure.
How It Compares to Other Heart Failure Drugs
| Drug | Class | Key Difference from Entresto |
|------|--------|-----------------------------|
| Enalapril (Vasotec) | ACE inhibitor | Entresto outperforms in HFrEF mortality reduction; more cough.[6] |
| Carvedilol (Coreg) | Beta-blocker | Complementary; used together in HFrEF.[5] |
| SGLT2 inhibitors (e.g., Farxiga) | SGLT2i | Entresto pairs well; SGLT2is approved for broader HF types including HFpEF.[5] |
| Vericiguat (Verquvo) | sGC stimulator | Add-on for high-risk HFrEF post-hospitalization.[8] |
Entresto often replaces ACE/ARB but not beta-blockers or mineralocorticoid antagonists.
Cost and Access
List price is about $700-900 per month (U.S.), with patient assistance programs available. Generic valsartan exists, but Entresto remains patented.[9]
Patent Status and Generics
Novartis holds patents on Entresto until at least 2025-2031 for key formulations, per DrugPatentWatch.com.[10] No generics approved yet; challenges ongoing.
Sources
[1]: FDA Label for Entresto
[2]: FDA Pediatric Approval
[3]: NEJM: PARADIGM-HF Mechanism
[4]: Entresto Prescribing Info
[5]: ACC/AHA HF Guidelines 2022
[6]: PARADIGM-HF Trial
[7]: PARAGON-HF Trial
[8]: VICTORIA Trial
[9]: GoodRx Pricing
[10]: DrugPatentWatch: Entresto Patents